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Abstract 
OBJECTIVE: To identify apparent adverse effects of treatment of chronic hepatitis C and 
their relationship to sustained virologic response (SVR). 
METHODS: A retrospective study was conducted of all Hepatitis C virus (HCV)-infected 
patients treated with pegylated interferon and ribavirin in an academic ambulatory infectious 
disease practice. Clinical and laboratory characteristics were compared between patients 
with SVR and without SVR.   
RESULTS: Fifty-four patients completed therapy with the overall SVR rate of 76%. SVR 
was associated with genotype non-1 (P=0.01), weight loss more than 5 kilograms (P=0.04), 
end of treatment leukopenia (P=0.02) and thrombocytopenia (P=0.05). In multivariate analy-
sis, SVR was significant associated with HCV genotype non-1 (Adjusted Odd Ratio [AOR] 
15.22; CI 1.55 to 149.72; P=0.02), weight loss more than 5 kilograms, (AOR 5.74; CI 1.24 to 
26.32; P=0.04), and end of treatment white blood cell count level less than 3 X 10
3 cells/µl 
(AOR 9.09; CI 1.59 to 52.63; P=0.02). Thrombocytopenia was not significant after adjust-
ment. Other factors including age, gender, ethnicity, injection drug use, viral load, anemia, 
alanine transaminase level, and liver histology did not reach statistical significance. 
CONCLUSION: Besides non-1 genotype, SVR was found to be independently associated 
with weight loss during therapy, and leukopenia at the end of HCV treatment. These cor-
relations suggest continuation of therapy despite adverse effects, may be of benefit. 
Key words: Hepatitis C, pegylated interferon, ribavirin, weight loss, leukopenia, thrombocyto-
penia. 
INTRODUCTION 
Hepatitis C virus (HCV) infection is a major 
cause of liver diseases and liver cancer (1-3). Among 
the six genotypes of HCV, the most common geno-
types of HCV in the United States are genotype 1 
(approximately 75%), genotype 2 (15%), and geno-
type 3 (7%) (2-5). At present, the standard treatment 
for chronic HCV genotype 1 infection is 48 weeks 
with a combination of pegylated (long-acting) inter-
feron alfa-2a or alfa-2b plus ribavirin. Outcomes are 
measured by sustained viral response (SVR), defined 
as an undetectable viral load 24 weeks after the end 
of therapy. HCV genotype 1 has been reported to 
have a 54-56% SVR (2, 6-9). Prior studies have shown 
better response rates with genotype 2 or 3 with a 24 
week-course of therapy (2, 8,9). Response rates have 
been found higher in Caucasians (52%) compared to Int. J. Med. Sci. 2010, 7 
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African-Americans (28%) (2). Response rates are re-
ported lower with initial levels of HCV RNA 
>600,000 IU/ml, male gender, high body weight, and 
advanced liver fibrosis (11-17). Recent studies have 
also shown a poorer response to treatment associated 
independently with HCV genotype1 infection but a 
better response with weight loss (18). Limited 
knowledge exists regarding the influence of 
on-treatment factors during therapy. The purpose of 
our analysis was to identify clinical, biological, vi-
rological and histological predictive factors that may 
be helpful in guiding decisions during therapy, and 
for counseling patients about outcomes. 
MATERIALS AND METHODS 
Study population. We conducted a retrospective 
cohort study of 54 adults (age ≥ 1 8  y e a r s )  p a t i e n t s  
who were diagnosed with HCV infection and com-
pleted treatment with pegylated interferon plus ri-
bavirin through an academic ambulatory infectious 
disease practice from January 2004 to December 2007. 
The study was approved by the University of Hawaii 
Committee on Human Studies (CHS # 1541). Patients 
infected with HCV genotype 1 completed a 48 
week-course with once weekly injections of pegylated 
interferon alfa-2a or alfa 2b (180 μg) plus ribavirin 
(1000 or 1200 mg/day in divided dose) for 48 weeks. 
Patients infected with HCV genotypes 2 or 3 com-
pleted a 24 week-course with once weekly injections 
of pegylated interferon alfa-2a (180 μg) plus ribavirin 
(800 mg/day in divided doses). SVR rates were 
measured at 24 weeks after the end of therapy. Inter-
feron dosing was not adjusted but ribavirin occasion-
ally was. Hematology growth factors were occasion-
ally used but not consistently. 
Study design and definitions. The study patients 
were identified from the clinic’s medical records us-
ing the International Statistical Classification of 
Diseases and Related Health Problems (ICD) code of 
070.44 and 070.54. During the period of study, 78 pa-
tients started on therapy. Twenty four patients were 
not included in the study analysis due to fail to com-
plete treatment and evaluation. Of these, 13 failed to 
return for follow-up, 6 stopped because of adverse 
effects, 3 for poor response, and 2 because of death. 
Finally, a total of 54 charts were reviewed in the pa-
tients who completed therapy and returned for fol-
low-up at 24 weeks after treatment. Information on 
demographic characteristics, co-morbid conditions, 
genotypes of HCV, laboratory data, treatment, and 
follow-up data were collected by using a study data 
collection form. SVR was indicated by undetectable 
HCV RNA at 24 weeks after therapy with combined 
pegylated interferon alfa-2a or alfa-2b plus ribavirin. 
Genotypes of HCV were defined using the Bayer 
TRUGENE HCV Genotyping Test. Serum concentra-
tion of HCV RNA was determined shortly before 
study and at 24 weeks after complete course of treat-
ment (treatment duration: 48 weeks in genotype 1 
a n d  2 4  w e e k s  i n  g e n o t y p e  2  o r  3 )  b y  t h e  C O B A S T  
(TaqMan) test, which has a limit of detection of 28 
IU/mL.  Body weight measurement and laboratory 
data were collected and compared at the beginning 
and at the end of therapy. The Knodell scoring sys-
tem for liver biopsy (obtained at baseline) result was 
used as the indicator of histologic activity.   
Statistical analysis. Descriptive statistics were 
produced comparing SVR versus non-SVR group. 
Categorical variables were compared using the Pear-
son’s χ2 or Fisher’s exact test, as appropriate. The dis-
tribution of continuous data was evaluated by the 
O’Brien test for homogenicity of variances. When 
necessary, an appropriate normalizing or variance 
stabilizing transformation was applied. Analysis of 
variance was used to compare groups. Cut-offs of 
continuous data was determined by evaluating the 
median results of the groups and deciding among the 
investigators clinical importance. From the data, 
clinically relevant cut-offs determined by the investi-
gators were as follows: for weight loss (more than 5 
kilograms.), leukopenia (WBC less than 3x103cells/µl) 
and thrombocytopenia (platelets less than 1x 105 
cells/µl). Logistic regression and multivariate analy-
sis were performed to identify independent predic-
tors for SVR. Statistical significance was considered 
with P value of 0.05. Odds ratio (OR) with 95% con-
fidence interval (CI) was reported in categorical data. 
All statistical analyses were conducted using SPSS for 
Window software, version 15.0 (SPSS Inc, Chicago, 
IL).  
RESULTS 
A total of 54 medical records of patients who 
completed HCV therapy with follow-up viral load 
result at 24 weeks were reviewed. The majority of the 
study population was male (67%) and Caucasian 
(57%) with the mean age of 52.5 years (Table 1). Fifty 
six percent were infected with genotype 1, 16% with 
genotype 2 and 28% with genotype 3. Clinical char-
acteristics, relevant laboratory data and liver biopsy 
results of all patients are shown in Table 1. The major 
risk factors for acquiring HCV infection were related 
to injection drug use and tattooing. Mild and moder-
ate liver inflammation determined by Knodell score 
was presented in the majority of patients while cir-
rhosis was rarely observed. A total of 22 patients had 
liver fibrosis: portal fibrosis was the most common 
(n=11, 50%), followed by septal fibrosis (n=4, 18%), Int. J. Med. Sci. 2010, 7 
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bridging fibrosis (n=4, 18%), periportal fibrosis, and 
only one patient with cirrhosis pattern (n=1, 5%). 
Forty-one percent of the patient population had a 
history of alcohol abuse and 35% had underlying 
psychiatric problems. Concomitant psychiatric dis-
orders among this patient population included de-
pression (38%), anxiety (18%), schizophrenia (6%) 
and bipolar disorder (3%). Underlying medical prob-
lems included hypertension (15%) and diabetes mel-
litus (DM) (14%).   
Demographics, clinical and laboratory data of 
patients (percent and means) were compared be-
tween patients with SVR and without SVR as shown 
in Table 2. All continuous variables were normally 
distributed and did not require log transformation. 
SVR was significantly affected by genotype non-1 
(P=0.01) as well as low white blood cell (WBC) count 
(leukopenia) at the end of treatment (P=0.02) com-
pared to patients without SVR. Moreover, low plate-
let count (thrombocytopenia) at the end of treatment 
was associated with SVR (P=0.05). Age, ethnicity, 
gender, drug abuse, and histology were not signifi-
cantly associated with SVR. To allow for clinical ap-
plicability, logistic regression with clinical cut-offs in 
the significant relevant covariants, found in the linear 
regression models, were performed. Laboratory 
characteristics and categorical variables for the pre-
dictors of SVR were compared by using logistic re-
gression and multivariate analysis (categorical data) 
as displayed in Table 3. In multivariate analysis, SVR 
was significant associated with HCV genotype non-1 
(Adjusted Odd Ratio [AOR] 15.22; CI 1.55 to 149.72; 
P=0.02), weight loss more than 5 kilograms, (AOR 
5.74; CI 1.24 to 26.32; P=0.04), and end of treatment 
white blood cell count level less than 3 X 103 cells/µl 
(AOR 9.09; CI 1.59 to 52.63; P=0.02). Thrombocyto-
penia was not significant after adjustment. Other fac-
tors including age, gender, ethnicity, injection drug 
use, viral load, anemia, alanine transaminase level, 
and liver histology and did not reach statistical sig-
nificance. 
Table 1: Baseline demographic, clinical characteristics and laboratory data of the study population 
Characteristics 
 
Total, n = 54
Male gender, n (%)  36 (67) 
Ethnicity, n (%)   
Caucasian  31 (57) 
Asian  10 (19) 
Hispanic  7 (13) 
Hawaiian  6 (11) 
 
 
 
 
 
Others  3 (6) 
Age, years, mean ± SD    52.5±5.8 
HCV genotypes, n (%)   
Genotype 1  30 (56) 
Genotype 2  9 (16) 
 
 
 
Genotype 3  15 (28) 
Weight, kilograms, mean ± SD  85.0± 19.1 
BMI, kilograms/m2, mean ± SD  28.2±5.5 
Baseline HCV RNA (x 106 IU/mL ± SD)  6.45±13.4 
HCV RNA > 600,000 IU/mL, n (%)  47 (87) 
ALT >90 U/L, n (%)  45 (83) 
Total bilirubin, mg/dlL, mean ± SD  1.0±0.5 
Serum albumin, g/dl, mean ± SD  3.9±0.3 
Liver biopsy results;   n = 38  
Knodell score, mean ± SD  8.0 ± 3.2 
Minimal inflammation (≤4), n (%)  4 (11) 
Mild inflammation (5-8), n (%)  18 (47) 
Moderate inflammation (9-12), n (%)  14 (37) 
 
 
 
 
 
Marked inflammation (≥13), n (%)  2 (5) 
Risk factors for acquiring HCV infection, n (%)   
Injection drug use  38 (70) 
Tattooing  41 (76) 
Sexual partners with HCV infection  10 (19) 
 
 
 
 
Blood transfusion  5 (9) Int. J. Med. Sci. 2010, 7 
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History of cocaine use, n (%)  22 (41) 
History of alcohol abuse, n (%)  22 (41) 
History of methamphetamine use, n (%)  2 (4) 
HIV co infection, n (%)  3 (6) 
Underlying psychiatric disorders (depression, bipolar disorder, schizophrenia and anxiety), n (%) 19 (35) 
Underlying medical conditions (diabetes mellitus, hypertension, others), n (%)  28  (52) 
Abbreviations: ALT = alanine transminase; BMI = body mass index; HCV = hepatitis C virus; HIV = human immunodeficiency virus; RNA 
= ribonucleic acid; SD = standard deviation. 
 
Table 2: Comparison of demographics, clinical characteristics and laboratory data between patients with and without 
sustained virological response (SVR). 
Characteristics  Patients with SVR
(n=41 ) 
Patients without SVR (n=13) P-Value
Male gender, n, (%)  30 (73)  6 (46)  0.11 
Caucasians, n (%)  23 (56)  8 (62)  0.94 
Age <50 years, n (%)  25 (60)  10 (77)  0.24 
Genotype 1, n (%)  18 (44)  12 (92)  0.01* 
Risk factors for acquiring HCV infection, n (%)   
 
 
 
 
 
  Injection drug use  26 (63)  12 (92)  0.28 
  Blood transfusion  4 (10)  1 (8)  0.21 
Baseline characteristic and risk factors      
  Alcohol abuse, n (%)  14 (47)  8 (62)  0.22 
  Cocaine use, n (%)  13 (32)  7 (54)  0.15 
  Methamphetamine use, n (%)  0 (0)   2 (15)   0.15 
  HIV co-infection, n (%)  1 (3)   2 (15)  0.47 
  Psychiatric disorders, n (%)  14 (34)  5 (38)  0.75 
  Knodell score < 11, n (%)  16 (64)a 10  (77)b 0.07 
  HCV RNA (x106 IU/mL, mean ± SD)   4.6±5.6  8.3±15.6  0.22 
  Weight (kilograms, mean ± SD)  92.1±22.2  77.9±16.0  0.10 
Baseline laboratory data      
  WBC (X 103 cells/µl, mean ±SD) 6.6±3.1  6.8±2.8 0.97 
  Hemoglobin (g/dl, mean ± SD)  15.3±0.9  14.8±1.2  0.91 
  Platelet (X 105 cells/µl, mean ± SD)  184.0±93.8  239.7±99.7  0.14 
  ALT (U/L, mean ± SD)  78.5±70.5  63.6±28.8  0.31 
  Total bilirubin (g/dl, mean ± SD)  1.1±0.7 0.8±0.2  0.47 
  Albumin (g/dl, mean ± SD)  3.8±0.4  4.0±0.2  0.10 
End of treatment laboratory data      
  WBC (X 103 cells/µl, mean ± SD)  2.9 ±1.1  3.6±0.9  0.02* 
  Hemoglobin (g/dl, mean ± SD)  11.8 ± 1.8   11.7±1.5  0.42 
  Platelet (X 106 cells/µl, mean ± SD)  122.4 ± 96.8  207.2±86.5  0.05* 
  ALT (U/L, mean ± SD)  35.3 ± 26.8  36.6±28.1  0.60 
  Total bilirubin (g/dl, ) mean ± SD)  1.4 ± 1.4  0.8± 0.3  0.13 
  Albumin (g/dl, mean ± SD)  3.8 ±0.3  3.8±0.5  0.95 
Clinically significance relevantce characteristic and laboratory data     
  Weight loss > 5 Kilograms, n (%)  29 (71)  5 (38)  0.04* 
  End of treatment WBC count less than 3 X 103 cells/µl  34 (83) 3  (23)  0.01* 
  End of treatment platelet count less than 1X 105 cells/µl  36 (88) 7(54)  0.06 
Note: * Statistical significant. Biopsy results; a total n for SVR = 25; b total n for non SVR =13.  
Abbreviations: ALT = alanine transminase; HCV = hepatitis C virus; RNA = ribonucleic acid; SD = standard deviation; SVR = sustained 
virological response; WBC = white blood cell count. 
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Table 3: Logistic regression and multivariate analysis for the predictors of SVR (Clinical significance relevance characteristic 
and laboratory data) 
Variables 
 
OR 
(95% CI) 
 
P-value
 
Adjusted# OR 
(95% CI)   
P-value 
Age < 50 year 
 
2.5 
(0.57-10) 
0.24 
 
1.38 
(0.23-8.33) 
0.73 
 
Genotype Non-1 
 
15.33 
(1.82-129.18)
0.01* 
 
15.22 
(1.55-149.72) 
0.02* 
 
Weight loss more than 5 kilograms  3.86  
(1.05-14.82) 
0.04* 
 
5.74  
(1.24-26.32) 
0.04* 
 
End of treatment WBC count less than 3 X 103 cells/µl  9.52  
(1.86-50.00) 
0.01* 
 
9.09  
(1.59-52.63) 
0.02* 
 
End of treatment platelet count less than 1X 105 cells/µl 6.9 
(0.8-5.9) 
0.06  2.43  
(0.13-45.45)  
0.51 
 
Note: * Statistical significant. # Model adjusted with all table variables.   
Abbreviation; CI = confidence interval; OR = odds ratio; SVR = sustained virological response; WBC = white blood cell. 
 
DISCUSSION 
The overall rate of response was 76% compara-
ble with those reported in the previous US studies of 
55%. Responses were better for both genotype 1 (56% 
vs 52%) and others (96% vs 81-84%).2 Our study 
strongly indicated that being infected with HCV 
genotype 1 was associated with treatment failure. The 
higher treatment response in our study compared to 
the US literatures may have occurred from differ-
ences in our demographic population. Our study had 
less African Americans (only 1 patient), and a lower 
prevalence of HCV genotype 1 and HIV co –infection. 
Higher response rates among Asians have been noted 
before. This may be related to the IL28B gene poly-
morphism as it is apparently associated with higher 
response to treatment among Asian Americans pa-
tients compared to Caucasians, Hispanics and Afri-
can Americans, respectively (19). 
In our study, the patients with SVR had signifi-
cant weight loss compared to those without SVR. The 
association between body weight, weight loss and 
SVR is controversial. Some previous studies showed 
that initial body weight is an independent risk factor 
for HCV treatment failure, and weight reduction was 
associated with treatment success (10, 20). However, 
other studies demonstrated that weight loss did not 
improve the treatment outcomes (15, 21). It is known 
that interferon therapy is associated with weight loss, 
but the mechanism and pathophysiology are still un-
clear. The reasons for weight loss among the study 
population are unclear. Many patients complained of 
loss of appetite or ate less related to the fatigue. 
Studies suggest that interferon decreases appetite via 
induction of tumor necrosis factors (TNF), the level of 
leptin, insulin and cytokines but findings are not con-
sistent (21-24). Alternatively, several studies showed 
that TNF levels were not increased during interferon 
therapy and postulated other mechanisms of weight 
loss including changes in level of leptin and insulin 
which affect glucose metabolism (21, 22). In our stud-
ies, weight loss usually began within the first few 
dosages of interferon treatment. It was also associated 
with fatigue, nausea, vomiting. The weight loss was 
usually sustained during therapy or gradually pro-
gressed. On the follow-up after complete treatment, 
patients usually gained weight but did not achieve 
their baseline bodyweight.   
In our study, patients with SVR had signifi-
cantly lower WBC and platelet count at the end of 
treatment compared to those without SVR. These 
findings suggested that patients who developed leu-
kopenia and/or thrombocytopenia during the inter-
feron treatment responded well to the therapy and 
these side effects, if not severe, may not be indications 
for withholding or reducing the dose of the treat-
ment. We hypothesized that the greater cytopenia is a 
marker for greater TNF activity in a specific treat-
ment recipient which translates into greater SVR. 
Common side effects of interferon treatment that 
need to be monitored during the therapy are anemia, 
thrombocytopenia and leukopenia (25-29). These side 
effects may prevent physicians from continuing their 
patients on interferon therapy or reducing dosage (28, 
29). A comparison of outcome by the approach of re-
ducing interferon and/or ribavirin versus use of 
growth factors to stimulate promotion of white blood 
cell or red blood cell or platelet counts has not been 
done but is clearly needed. We believe that the dif-
ferences in magnitude of interferon effects on indi-
vidual pharmacokinetics, pharmocodynamics, and 
genetic determination of interferon susceptibility may 
play an important role in each patient’s treatment 
response and side effect experience. 
Our patients had a high rate of mental illnesses 
and social problems because of our open referral sys-Int. J. Med. Sci. 2010, 7 
 
http://www.medsci.org 
41
tem and the population at risk. However, the major-
ity of patients tolerated HCV treatment which can be 
attributed to our supportive staff and follow-up sys-
tem. The potential interaction between psychiatric 
illness and its treatment with HCV therapy could not 
be assessed with our limited study. 
This study is limited in that it is retrospective 
and examined only subjects who completed HCV 
therapy. The association of SVR with factors reported 
b y  o t h e r s ,  s u c h  a s  a g e ,  h i s t ological (fibrosis) score, 
viral load and alanine transminase level was not sig-
nificant in our study. This may be related to the small 
sample size. Other factors such as adherence and in-
sulin resistance were not assessed. The majority of 
patient with genotype 2 and 3 did not have liver bi-
opsy reports. Further studies with larger sample size 
and molecular testing may enhance our understand-
ing of the relationship between interferon and antivi-
ral therapy in chronic hepatitis C infection. 
In conclusion, the virological outcomes of the 
current HCV infection therapy in our study were 
comparable with the outcomes of the previous stud-
ies. The treatment failure was significantly associated 
with genotype 1. Side effects of interferon therapy 
including leukopenia, thrombocytopenia and weight 
loss were predictors of good treatment response. 
Giving these findings, a careful assessment is needed 
in regards to continuing therapy with interferon and 
ribavirin despite opposed adverse effects by labora-
tory parameters and weight loss.   
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